Find your next paid study

M.D. Anderson Cancer CenterNCT06287229

AML (Acute Myeloid Leukemia)

A Phase 1/2, Multicenter, First-in-Human, Dose Escalation and Expansion Study Evaluating CHM-029 as Monotherapy in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) With NPM1 Mutations, KMT2A or NUP98 Rearrangements

The goal of this study is to evaluate the safety of CHM-029, an investigational oral medicine, and to evaluate its activity in treating certain types of acute …

Charm TherapeuticsNCT07751991

~$10 – $8,750

B-Cell LymphomaMyelodysplastic Syndromes (MDS)Acute Myeloid Leukemia (AML)+7 more

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients wit…

M.D. Anderson Cancer CenterNCT05092451

Phase 2

The MAVRiC Study: A Phase II Study of Disease Risk Mutation Guided Finite Duration Acalabrutinib Plus Venetoclax for Relapse in CLL/SLL After First-line Finite Covalent BTKi Plus BCL2i Combination, With or Without Obinutuzumab

This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, and have previo…

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)

~$10 – $7,500

AstraZenecaNCT07024706

Recurrent Childhood Acute Myeloid LeukemiaRefractory Childhood Acute Myeloid Leukemia

A Phase 1 Study of FOLR1 CAR T for Pediatric Patients With FOLR1/CBFA2T3::GLIS2+ Relapsed or Refractory AML

This phase I trial tests the safety, side effects, and best dose of FH-FOLR1 chimeric antigen receptor (CAR) T cells in treating pediatric patients with FOLR1+…

Fred Hutchinson Cancer CenterNCT06609928

B-cell Acute Lymphoblastic LeukemiaLarge B-cell LymphomaChronic Lymphocytic Leukemia+10 more

A Phase 1/2 Safety, Dose-finding, and Pharmacokinetics Study of VNX-101 Gene Therapy in Patients With Relapsed or Refractory CD19-Positive Hematologic Malignancies (SENTRY-CD19)

This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refra…

Vironexis Biotherapeutics Inc.NCT06533579

~$10 – $8,750

Phase 2

Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors

This Phase II hybrid decentralized multicenter study examines the outcomes of stopping Bruton tyrosine kinase inhibitor (BTKi) therapy in patients with chronic…

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

UNC Lineberger Comprehensive Cancer CenterNCT07526597

Observational

Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL)

Acute lymphoblastic leukemia (ALL) is the most common cancer in children and, along with lymphoblastic lymphoma, represents the most common group of childhood …

LeukemiaAcute LeukemiaAcute Lymphoid Leukemia+2 more

UNC Lineberger Comprehensive Cancer CenterNCT07634653

Observational

Mosaic: RCT of a Digital Health Intervention for English- and Spanish-speaking Stem Cell Transplant Recipients

The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patient…

Hematologic MalignancyStem Cell TransplantBone Marrow Transplant+4 more

Northwestern UniversityNCT06960993

Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid LeukemiaAcute Leukemia of Ambiguous Lineage

A Phase 1 Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effect…

St. Jude Children's Research HospitalNCT06177067

CLL / SLLCLL (Chronic Lymphocytic Leukemia)SLL (Small Lymphocytic Lymphoma)+2 more

Phase 1 Study of Lonitoclax (ZE50-0134) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and Select Low-grade Lymphomas

This Phase 1, open-label, multicenter study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of l…

Lomond Therapeutics Holdings, Inc.NCT06708897

~$10 – $8,750

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome

Phase I Study of Escalating Doses of 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

This phase I trial tests the safety, side effects, best dose, and effectiveness of 225Ac-DOTA-Anti-CD38 daratumumab monoclonal antibody in combination with flu…